Mavrommatis Maria A, Jung Hoon, Chari Ajai, Barlogie Bart, Chelnis James G
Icahn School of Medicine at Mount Sinai, 1468 Madison Ave, New York, NY, 10029, USA.
Department of Ophthalmology, University of Washington, Box 259608 325 Ninth Avenue, Seattle, WA, 98104, USA.
Am J Ophthalmol Case Rep. 2018 Dec 18;13:116-118. doi: 10.1016/j.ajoc.2018.12.017. eCollection 2019 Mar.
To describe an unprecedented case of transient myopic shift induced by a chemotherapeutic agent, daratumumab.
A 43-year-old emmetropic female with multiple myeloma experienced sudden onset of myopic shift during her first intravenous dose of daratumumab, an increasingly common FDA-approved chemotherapeutic agent. Her myopia was corrected with -4D lenses in both eyes, and the patient reports cessation of symptoms and disuse of lenses after two days.
A number of medications have been documented to induce transitory myopic shift, and this report now includes daratumumab among such agents. Further clinical findings regarding the mechanism and frequency of daratumumab-induced myopic shift are needed to further develop our understanding of its tangential effect on the eye.
描述一例由化疗药物达雷妥尤单抗引起的前所未有的短暂性近视偏移病例。
一名43岁的正视眼女性多发性骨髓瘤患者，在首次静脉注射达雷妥尤单抗（一种美国食品药品监督管理局批准的日益常见的化疗药物）时突然出现近视偏移。她的双眼近视用-4D镜片矫正，患者报告两天后症状消失且不再使用镜片。
已有多种药物被记录可诱发暂时性近视偏移，本报告现在将达雷妥尤单抗纳入此类药物。需要关于达雷妥尤单抗诱导近视偏移的机制和频率的进一步临床研究结果，以加深我们对其对眼睛的附带影响的理解。
